Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02553642 2025-07-22

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Phase 2 Completed

81 enrolled 12 charts

DermatologicGenitourinary

Urinary Bladder Neoplasms, Melanoma

NCT05116202 2025-07-18

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Phase 1/2 Completed

110 enrolled 27 charts

Dermatologic

Melanoma

NCT02743819 2025-06-10

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Phase 2 Active not recruiting

70 enrolled 11 charts

Dermatologic

Melanoma

NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

Phase 1/2 Completed

41 enrolled 15 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

Dermatologic

Melanoma

NCT01703507 2025-05-16

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Phase 1 Completed

17 enrolled 15 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 2 FDA

Dermatologic

Melanoma

NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Phase 2 Completed

14 enrolled 8 charts

Dermatologic

Uveal Melanoma

NCT03719131 2025-04-22

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Phase 2 Active not recruiting

15 enrolled 10 charts

Dermatologic

Melanoma

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Phase 2 Completed

156 enrolled 11 charts

Dermatologic

Melanoma

NCT03009058 2024-11-25

MODULATE

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT02027935 2024-10-08

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 2 Completed

16 enrolled 8 charts

Dermatologic

Melanoma

NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2 Terminated

4 enrolled 11 charts

Dermatologic

Melanoma

NCT01585194 2024-07-09

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 2 Completed

67 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT01119508 2024-06-06

Ipilimumab + Temozolomide in Metastatic Melanoma

Phase 2 Completed

64 enrolled 6 charts

Dermatologic

Melanoma

NCT04655157 2024-05-23

QUAD01

Phase 1/2 Terminated

2 enrolled 12 charts

Dermatologic

Melanoma

NCT02107755 2024-05-21

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 2 Completed

8 enrolled 12 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01740297 2024-05-14

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Phase 1/2 Completed

217 enrolled 27 charts

Dermatologic

Melanoma

NCT02970981 2024-04-30

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Phase 2 Completed

18 enrolled 8 charts

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Phase 2 Completed

16 enrolled 14 charts

Dermatologic

Melanoma

NCT01621490 2024-04-23

PD-1

Phase 1 Completed

170 enrolled 34 charts

Dermatologic

Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

Phase 2 Completed

53 enrolled 10 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT02978443 2024-04-04

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Phase 2 Terminated

14 enrolled 12 charts

Dermatologic

Melanoma

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Phase 1 Terminated

22 enrolled 14 charts

Dermatologic

Melanoma

NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Phase 1 Terminated

3 enrolled 5 charts

DermatologicGastrointestinalLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Colonic Neoplasms, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01856023 2023-12-05